January 13, 2021

GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®

Bilateral improvement in visual acuity from a unilateral injection of gene therapy – consistent with REVERSE trial findings Significant improvement against visual ...
Read more
January 7, 2021

CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies

PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced tod...
Read more
January 6, 2021

Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021

-CAHmelia Adult Classic CAH Program Underway in U.S. and Europe- -Initiation of Phase 2 Pediatric Classic CAH Program Anticipated in Second Half of 2021- -Initiation of Phase 2 P...
Read more
January 6, 2021

Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update

 Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Perc...
Read more
January 6, 2021

Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore

COVID-19 have caused delays to submission and processing of the regulatory application to initiate clinical development in China Due to the unforeseen delays, Targovax has e...
Read more
January 5, 2021

Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines

- Aro’s proprietary Centyrin technology platform enables precise receptor-mediated delivery of RNA drugs to address intracellular gene targets - Funding will help advance lead...
Read more
December 30, 2020

Orexo announces new US patent for ZUBSOLV®

Uppsala, Sweden – December 30, 2020 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for Z...
Read more
December 28, 2020

Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)

The trial failed to meet its primary endpoint of complete remission (CR) rate CR rate was 53% higher in eprenetapopt with AZA arm compared to AZA alone, but did not reach st...
Read more
December 21, 2020

Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma

STOCKHOLM — December 21, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE...
Read more
December 21, 2020

Positive results show that C21 can become an important complement to COVID-19 vaccines

Gothenburg, December 21, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, today report...
Read more
Older news →